CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Intrathecal (injected into the spinal fluid) DepoCyt +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00029523
NCT00029523Phase 4Completed
CompareCT.gov

A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis

Pacira Pharmaceuticals, Inc·interventional·Posted Jan 16, 2002·Updated Feb 28, 2007

In Brief

A Phase 4 clinical trial evaluating Intrathecal (injected into the spinal fluid) DepoCyt, Intrathecal methotrexate, and 1 other intervention for Meningeal Neoplasms. Completed, across 23 sites in 2 countries.

Detailed Summary

The purpose of this study is to find out how well an experimental drug called DepoCyt works for neoplastic meningitis (cancer that has spread to the tissues around the brain and spinal cord). DepoCyt is a new slow-release form of the cancer drug called ara-C (cytarabine). Cytarabine has been used for many years to treat cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningeal Neoplasms
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 16, 2002
Enrollment StartApr 1, 2001
Study CompletionNov 1, 2004
TodayJul 2, 2026
Posted 24.5 years ago

Interventions

Intrathecal (injected into the spinal fluid) DepoCytdrug

Intrathecal methotrexatedrug

Intrathecal cytarabine (also known as ara-C)drug